Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Article first published online: 8 OCT 2012
Copyright © 2012 Wiley Periodicals, Inc.
The Anatomical Record
Special Issue: The Anatomy and Biology of Hearing and Balance: Cochlear and Vestibular Implants
Volume 295, Issue 11, pages 1837–1850, November 2012
How to Cite
Schacht, J., Talaska, A. E. and Rybak, L. P. (2012), Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention. Anat Rec, 295: 1837–1850. doi: 10.1002/ar.22578
- Issue published online: 22 OCT 2012
- Article first published online: 8 OCT 2012
- Manuscript Accepted: 24 JUL 2012
- Manuscript Received: 28 NOV 2011
- National Institutes of Health (National Institute for Deafness and Communication Disorders). Grant Numbers: DC 003685, DC 02396
- oxidative stress;
This review introduces the pathology of aminoglycoside antibiotic and the cisplatin chemotherapy classes of drugs, discusses oxidative stress in the inner ear as a primary trigger for cell damage, and delineates the ensuing cell death pathways. Among potentially ototoxic (damaging the inner ear) therapeutics, the platinum-based anticancer drugs and the aminoglycoside antibiotics are of critical clinical importance. Both drugs cause sensorineural hearing loss in patients, a side effect that can be reproduced in experimental animals. Hearing loss is reflected primarily in damage to outer hair cells, beginning in the basal turn of the cochlea. In addition, aminoglycosides might affect the vestibular system while cisplatin seems to have a much lower likelihood to do so. Finally, based on an understanding the mechanisms of ototoxicity pharmaceutical ways of protection of the cochlea are presented. Anat Rec, 2012. © 2012 Wiley Periodicals, Inc.